ONC:CA Oncolytics Biotech Inc.Stock Price & Overview
$1.54
Charts
Quant Ranking
ONC:CA Analysis
ONC:CA News
Latest Headlines
Ratings Summary
People Also Follow
Similar to ONC:CA
ETFs Holding ONC:CA
ONC:CA Company Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
ONC:CA Revenue
ONC:CA Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
ONC:CA Ownership
ONC:CA Peers
Risk
Technicals
ONC:CA Transcripts
Investor Presentations
ONC:CA SEC Filings
Press Releases
ONC:CA Income Statement
ONC:CA Balance Sheet
ONC:CA Cash Flow Statement
ONC:CA Long Term Solvency
Discover More
You may be interested in: